A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Intravenous (IV) Ulimorelin Administered Post-Operatively to Accelerate Recovery of Gastrointestinal (GI) Motility in Subjects Who Have Undergone Partial Bowel Resection
Latest Information Update: 09 Sep 2024
At a glance
- Drugs Ulimorelin (Primary)
- Indications Gastrointestinal motility disorders
- Focus Therapeutic Use
- Acronyms ULISES; ULISES 008
- Sponsors Ocera Therapeutics
Most Recent Events
- 07 Nov 2014 New trial record